Company name ANSYS, Inc.
Stock ticker ANSS
Live stock price [stckqut]ANSS[/stckqut]
P/E compared to competitors Fair

MANAGEMENT EXECUTION

Employee productivity Good
Sales growth Good
EPS growth Good
P/E growth Good
EBIT growth Good

ANALYSIS

Confident Investor Rating Good
Target stock price (TWCA growth scenario) $101.22
Target stock price (averages with growth) $129.6
Target stock price (averages with no growth) $94.09
Target stock price (manual assumptions) $101.96

The following company description is from Google Finance: http://www.google.com/finance?q=anss

ANSYS, Inc. (ANSYS) develops and globally markets engineering simulation software and services used by engineers, designers, researchers and students across a range of industries and academia, including aerospace, automotive, manufacturing, electronics, biomedical, energy and defense. The Company distributes its ANSYS suite of simulation technologies through a global network of independent resellers and distributors (collectively, channel partners) and direct sales offices in global locations. The Company’s product portfolio consists of ANSYS Workbench, multiphysics product, structural mechanics, fluid dynamics, explicit dynamics, electromagnetic, system simulation, simulation process and data management, academic, high-performance computing (HPC), geometry interfaces, meshing and Apache design low-power electronic solutions. On August 1, 2011, the Company acquired Apache Design, Inc. In April 2013, it acquired EVEN – Evolutionary Engineering AG.

 

Confident Investor comments: At this price and at this time, I think that a Confident Investor can confidently invest in this stock.

If you would like to understand how to evaluate companies like I do on this site, please read my book, The Confident Investor.
 

Most of the stock that is traded on the market is bought and sold by large institutional investors. At some point in the future, I will explain those ominous institutional investors and why they exist and where they get their money. If you want get an update when that article is published, you can simply follow me on Twitter at @ConfidentInvest, subscribe to my RSS feed, or subscribe to my weekly aggregation newsletter.

These institutional investors are not immune from the herd mentality of the market. In fact, they often drive it! They tend to be very susceptible to market analysts that put a rating on a particular stock such as Buy, Hold, Sell (or one of the other less obvious ratings). They also tend to give a lot of credence to target market pricing that is published by analysts.

The biggest disadvantage of the large institutional investors is simply their size! Their second disadvantage is their report to their investors. A quick discussion of these two points is relevant:

  1. One of the largest investment funds (i.e. mutual fund) is The Growth Fund of America (AGTHX). This fund has approximately 115 BILLION dollars under management!  This is larger than the GDP of a small country like Bangladesh or Morocco! When the fund managers are working with a portfolio this large they have massive investments in any one stock. In fact, according to their 2012 Annual Report their largest holding was $4.8B in Apple [stckqut]AAPL[/stckqut] and now, according to their site, Apple doesn’t make the top ten. When the managers liquidated this stock, they didn’t do it in one order – they had to do it over time. In fact, it is possible that the liquidation of this stock actually drove the stock price down so as they sold more shares, they were selling at lower and lower prices.
  2. The second point that is a disadvantage to mutual fund operators is the focus they get on publishing their largest holdings. If you saw a fund that had 5% of its money in Apple over the last 3-4 months wouldn’t you question the manager’s logic? This means that they are constantly under scrutiny on their top investments. A potential investor may disqualify AGTHX if they see Apple at the top of the list. The manager may think that it is time to buy Apple but the risk of the holdings report means that the investment has to be considered wise within the reporting period of the fund.

The advantage to you, an individual investor, is that you can quickly and efficiently buy or sell stock in any company. You can also take advantage of the herd mentality of the entire investment community: you can buy stocks when they have irrationally been beaten down too low, and you can sell them when market exuberance has overpriced a company.

As a small investor, you will not move the market no matter what you do, so you can remain calm and analyze each company to determine the best price to sell and the best price to buy. Your personal moves will not be noticed and start a run on any company. You can quietly and efficiently make your profit.

The key thing to remember is that, when you buy a stock, you may pay too much or you may get an excellent deal. It is only through analysis and research that you can make that determination. It is also essential to remember that most stocks are appropriately priced and will not be a bargain. You will need to be patient to find companies that are bargains. The tools that I describe in my book, The Confident Investor, will help you with that analysis. You can purchase my book wherever books are sold such as Amazon, Barnes and Noble, and Books A Million. It is available in e-book formats for Nook, Kindle, and iPad.

Company name American Tower Corp
Stock ticker AMT
Live stock price [stckqut]AMT[/stckqut]
P/E compared to competitors Fair

MANAGEMENT EXECUTION

Employee productivity Fair
Sales growth Good
EPS growth Good
P/E growth Fair
EBIT growth Good

ANALYSIS

Confident Investor Rating Good
Target stock price (TWCA growth scenario) $187.94
Target stock price (averages with growth) $219.86
Target stock price (averages with no growth) $142.49
Target stock price (manual assumptions) $123.6

The following company description is from Google Finance: http://www.google.com/finance?q=amt

American Tower Corporation is a holding company. The Company conducts its operations through its directly and indirectly owned subsidiaries and joint ventures. It is a wireless and broadcast communications infrastructure company that owns, operates and develops communications sites. Its primary business includes leasing antenna space on multi-tenant communications sites to wireless service providers, radio and television broadcast companies, wireless data providers, government agencies and municipalities and tenants in a number of other industries. This business is its rental and management operations. It also offer tower-related services domestically, including site acquisition, zoning and permitting services and structural analysis services, which primarily support its site leasing business and the addition of new tenants and equipment on its sites. In January 2012, the Company merged with and into American Tower REIT, Inc.

 

Confident Investor comments: At this price and at this time, I think that a Confident Investor can confidently invest in this stock.

If you would like to understand how to evaluate companies like I do on this site, please read my book, The Confident Investor.
 

Company name Amazon.com, Inc.
Stock ticker AMZN
Live stock price [stckqut]AMZN[/stckqut]
Confident Investor Rating Poor

The following company description is from Google Finance: http://www.google.com/finance?q=amzn

Amazon.com, Inc. (Amazon.com), incorporated on May 28, 1996, serves consumers through its retail websites and focus on selection, price, and convenience. The Company also manufactures and sell Kindle devices. It offers programs that enable sellers to sell their products on its websites and their own branded websites and to fulfill orders through them , and programs that allow authors, musicians, filmmakers, app developers, and others to publish and sell content..The Company operates in two segments: North America and International. North America segment consists of amounts earned from retail sales of consumer products and subscriptions through North America-focused websites such as www.amazon.com and www.amazon.ca and include amounts earned from AWS. The International segment consists of amounts earned from retail sales of consumer products and subscriptions through internationally-focused websites. In May 2012, the Company acquired Kiva Systems, Inc. (Kiva).
Confident Investor comments: At this price and at this time, I do not think that a Confident Investor can confidently invest in this stock. It is not possible to confidently invest in a company that is not currently profitable. I am removing this stock from my Watch List. I have reviewed Amazon on this site several times and it has bounced between Fair and Good each time. The last time I reviewed it, the stock had dropped to Fair but I left it on my Watch List due to the company’s impact on the retail sector. While the stock is still very popular, I can no longer be confident in its growth potential as it tries to return to profitability.

If you would like to understand how to evaluate companies like I do on this site, please read my book, The Confident Investor.

Company name Alexion Pharmaceuticals, Inc.
Stock ticker ALXN
Live stock price [stckqut]ALXN[/stckqut]
P/E compared to competitors Fair

MANAGEMENT EXECUTION

Employee productivity Good
Sales growth Good
EPS growth Good
P/E growth Good
EBIT growth Good

ANALYSIS

Confident Investor Rating Good
Target stock price (TWCA growth scenario) $154.89
Target stock price (averages with growth) $200.16
Target stock price (averages with no growth) $125.48
Target stock price (manual assumptions) $154.26

The following company description is from Google Finance: http://www.google.com/finance?q=alxn

Alexion Pharmaceuticals, Inc. (Alexion) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its marketed product Soliris (eculizumab) is the first and only therapeutic approved for patients with two ultra-rare and severe disorders resulting from chronic uncontrolled activation of the complement component of the immune system: paroxysmal nocturnal hemoglobinuria (PNH), an ultra-rare and life-threatening blood disorder, and atypical hemolytic uremic syndrome (aHUS), an ultra-rare and life-threatening genetic disease. On February 7, 2012, it acquired Enobia Pharma Corp. (Enobia). On February 8, 2011, it acquired patents and assets from Orphatec Pharmaceuticals GmbH (Orphatec). On January 28, 2011, it acquired Taligen Therapeutics, Inc. (Taligen). It acquired Asfotase alfa in February 2012.

 

Confident Investor comments: At this price and at this time, I think that a Confident Investor can confidently invest in this stock.

If you would like to understand how to evaluate companies like I do on this site, please read my book, The Confident Investor.